Immuno-affinity purification of mouse E2F8 protein complexes by Tuttle, John
Immuno-affinity purification of mouse E2F8 protein complexes 
 
 
 
 
 
A Senior Honors Thesis 
 
 
 
 
 
Presented in partial fulfillment of the requirements for graduation with distinction in Molecular 
Genetics in the College of Biological Sciences of The Ohio State University 
 
 
 
By 
 
 
 
 
John Tuttle 
 
 
 
 
The Ohio State University 
 
May 2006 
 
 
 
 
 
 
 
 
Project Advisor: Dr. Gustavo Leone, Department of Molecular Virology, Immunology, and 
Medical Genetics 
 
 1
Abstract 
 The E2F family of genes has been extensively studied in the hope of gaining insight into the 
role of these DNA binding proteins.  The general function of all E2F proteins is to bind to DNA 
and regulate the expression of a multitude of genes responsible for cellular proliferation.  Given 
the central role the E2F family plays in the development and progression of cancerous cells, it is 
imperative to understand the pathways they are involved in and just how they are regulated. 
Shortly after the complete human and mouse genomes were finished, the final E2F family 
member was discovered: E2F8.  The characteristics of this gene have only begun to be 
satisfactorily identified.  It is known that the protein possesses two distinct DNA binding 
sequences, quite similar to its closely related family member E2F7.  Like E2F7, over-expressed 
E2F8 has shown an ability to inhibit cellular proliferation, which suggests that both proteins act 
as tumor suppressors.   
 A great majority of proteins do not function alone; they must interact with other proteins in 
order to fulfill their determined function in the overall metabolic scheme of the cell. If one is to 
understand the nature of a protein and the role it carries out in cellular pathways, the protein 
complexes in which the protein participates must be identified. 
 The specific aims of this project are to first express a tagged version of E2F8 in HeLa cells, 
and then to use that tagged protein as bait to isolate binding partners. To this end, a double-
tagged version of E2F8 is subcloned into a retroviral vector that couples the construct with the 
ILR2-alpha receptor sequence via an IRES.  The vector is transfected into Phoenix packaging 
cells which then produce human specific, infectious virions.  This virus is used to transduce 
HeLa cells and consequently over-express E2F8 ectopically.  Expression of E2F8 also 
constitutes IR2-alpha expression and this membrane receptor is used to enrich the E2F8 
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expressing cells through magnetic bead affinity.  Enrichment of E2F8 is confirmed by 
immunoblot analysis.  
 The over-expressing cell-lines are grown in large, 8 liter suspension culture batches in order 
to produce sufficient levels of protein for isolation and eventual mass-spectrometry analysis.  
The large batches are harvested and lysed in such a way as to isolate cytoplasmic content 
separately from nuclear.  This allows for a concentration of nuclear proteins, among which exist 
our complexes of interest.  The nuclear lysates are then allowed to bind to resin conjugated to 
antibody raised against one of the tagged sequences, in this case, FLAG.  The bound complexes 
are washed and then eluted.  This eluent is then further filtered by repeating the purification 
using another antibody bound matrix, in this case, HA (hemagglutinin peptide sequence).  The 
final elution is screened for E2F8 and binding partners via immunoblotting and silver staining, 
and once the identities are confirmed, they are sent out for mass-spectrometric analysis.  The 
relationship between E2F8 and its binding partners will be further pursued once this data is 
obtained. 
 
Introduction 
The E2F transcription factor family plays a large role in the regulation of the cell-cycle.  
The general function of all E2F proteins is to bind to DNA in a sequence specific manner and 
regulate the expression of a multitude of genes responsible for cellular proliferation.  If particular 
E2F pathways are somehow disrupted, unregulated cellular replication will inevitably ensue, and 
a tumor will form (21).  It has been shown that a disruption in the retinoblastoma pathway or an 
alteration in Cdk activity that leads to the deregulation of E2F is a property of virtually all cases 
of human cancer (14, 18).  Given the central role the E2F family plays in the development and 
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progression of cancerous cells, it is imperative to understand the pathways they are involved in 
and just how they are regulated. 
The E2F family is generally divided into at least two classifications: transcriptional 
activators or transcriptional repressors.  The E2Fs that are considered transcriptional activators 
include E2F1, E2F2, and E2F3a.  Their peak expression levels are found in the late G1 phase of 
the cell-cycle where they proceed to associate with E2F-regulated promoter regions during the 
G1-S transition.  These E2F target genes are transcribed and facilitate movement into S phase.  It 
has been demonstrated that over-expression of E2F is sufficient for S phase entry (15, 16) and 
that cells that have E2F1-3 inactivated are defective in G1-S transition (17), indicating that their 
role is vital in maintaining proficient and regulated cellular proliferation.  In contrast to the 
activator E2Fs, the repressors E2F3b, E2F4, and E2F5 are all expressed throughout the cell-
cycle, yet seem to function mainly in quiescent cells.  These proteins associate with E2F-target 
promoters throughout G0 (1-3).  In addition, E2F6 acts as a repressor by target promoter 
association facilitated by protein recruitment of polycomb group proteins or complex formation 
with Mga and Max proteins (4, 5).   
E2Fs 1-5 associate with the tumor suppressor protein Rb, which is necessary for 
controlled cellular division, differentiation, and apoptosis (13-15).  The E2F activator proteins 
are bound by Rb.  In the Rb-bound state they remain inactive until cyclin dependent kinases 
phosphorylate Rb and cause a conformational change in the protein which releases the E2F 
factor.  These released factors up-regulate E2F target genes which induces G1-S transition as 
described earlier.  Rb also associates with some of the repressor E2Fs.  In so doing, Rb recruits 
chromatin-remodeling complexes and DNA and histone-modifying enzymes such as DNA 
methyltransferases and HDACs, respectively (6-12).  These complexes are also cell-cycle 
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specific, in that phosphorylation of Rb causes the repressive complexes to dissociate.  E2F6, 
E2F7, and E2F8 do not contain Rb binding sequences.  However, E2F8 may be the only E2F not 
regulated by the Rb pocket proteins (5, 19, 20). 
E2Fs 1-6 are able to bind DNA in a sequence specific manner via their highly conserved 
DNA-binding and dimerization domains.  In order to bind DNA efficiently, these E2Fs must 
heterodimerize with DP1 or DP2 (13-15).  In contrast, E2F7 and E2F8 are unique in that they do 
not contain a dimerization domain but instead have a duplicated DNA-binding domain (19, 20).  
This allows these two proteins to bind DNA independent of DP1 and DP2.  Furthermore, there is 
evidence that E2F7 and E2F8 both homodimerize, and can actually form heterodimers with one 
another (19, 20, Li unpublished data).  This evidence suggests that E2F7 and E2F8 could have 
overlapping or even synergistic functions in the cell. 
Unlike E2F7, E2F8 does not code for transactivating regions or pocket protein binding 
domains.  E2F8 consists of 890 amino acids with an approximate weight of ~95 Kd.    The 
mouse tissues in which this protein is most highly expressed are the liver, skin, thymus, and 
testis, in contrast to the brain, muscle, and stomach, where E2F8 expression has not been 
detected or is too low for experimental consideration (19).  E2F8 exhibits a similar expression 
pattern as the activator E2Fs: they are all up-regulated at the G1/S transition (18).  However, 
E2F8 is not an activating protein, in fact, ectopic expression of E2F8 in MEFs (19) or human 
TIG3 fibroblasts (18) causes a marked inhibition of cellular proliferation and down-regulation of 
E2F target genes.  In addition, cells over-expressing E2F8 constructs bearing point-mutations in 
either of their DNA-binding domains do not exhibit either of these phenotypes and divide at a 
similar rate to wild-type cells (18, 19).  Therefore it is the ability of E2F8 to bind DNA in a 
sequence specific manner that allows it to negatively affect cellular proliferation.  Also, the 
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expression pattern of E2F8 suggests that it acts in a competitive manner with activator E2Fs for 
target promoters (18).   
 This experimental evidence indicates that E2F8 is a tumor suppressor candidate.  In order to 
elucidate the full capabilities of E2F8, we must know what biochemical interactions it undergoes 
in the cell.  It is known that E2F8 binds to DNA (18) and can form dimers (19).  Further studies 
are needed to discover what other proteins E2F8 interacts with in the nucleus.  Indeed, a great 
majority of proteins do not function alone; they must interact with other proteins in order to 
fulfill their determined function in the overall metabolic scheme of the cell.  In so doing, proteins 
form complexes (Fig. 1).  That is, two or more proteins bind together to form a quaternary 
structure that affords the ability to perform cellular functions, the likes of which the complexes’ 
components alone are not capable of, or cannot carry out with the same efficiency.  If we are to 
fully understand the potential of E2F8 and the role it carries out in cellular pathways, the protein 
complexes in which it participates must be identified (4).   
The aim of this experiment is to isolate E2F8 protein complexes from Hela cells and to 
identify novel binding partners via mass-spectrometric analysis.  In order to do so, E2F8 is 
tagged with two sequences specific for designated antibodies, in this case FLAG and HA. This 
construct is subcloned into a retroviral vector that also produces an ILR2-alpha receptor via an 
internal ribosomal entry site.  This vector is packaged and then used to transduce HeLa cells.  
Cells efficiently producing E2F8 are selected using magnetic beads coupled to antigen specific 
for the ILR2-alpha surface receptor.  Enriched cell lines are then grown up in large suspension 
culture batches and lysed.  The nuclear content is separated and the tags on the N-terminus of the 
E2F8 construct are used to purify and separate the complexes from other cellular matter (Fig. 2).  
The components of these complexes are determined by mass-spectrometric analysis.  Here we 
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identify two novel binding partners: HDAC1 and SIN3A.  This data was obtained via the 
described purification method followed by immunoblot analysis.  Results from the mass-
spectrometry labs ought to identify further E2F8 binding partners.   
 
Materials and Methods 
Retroviral Vector Subcloning: 
Standard subcloning protocols were employed to place the 2583 bp E2F8 sequence in frame with 
Flag and HA tags and an IRES and IL2Ralpha sequence, including Qiagen mini and maxi prep 
kits, PCR amplified segments and oligo sequences designed to include necessary restriction 
enzyme sites for proper placement of the construct in the pOZFHN retroviral vector.  Further 
subcloning was needed to also produce several mutant constructs of E2F8 within the pOZFHN 
plasmid, one with point mutations of the conserved leucine 118 and glycine 119 in the first DNA 
binding domain (DBD-1), another with point mutations of the conserved leucine 266 and 
arginine 267 in the second DNA binding domain (DBD-2), and a third with point mutations in 
both DNA binding domains (DBD-1,2).  Subcloning details are available upon request. 
 
Amphitropic Phoenix Packaging Cell Line Transfection:  
Amphitropic phoenix retrovirus packaging cells were thawed and split according to standard 
tissue culture protocol.  CaCl2 and HBS were thawed from -20ºC in a 37ºC water bath.  
Approximately 25 ug of plasmid DNA per p100 was added to 1 ml of CaCl2 per p100.  While 
bubbling 1 ml of HBS per p100 with a pipette, the CaCl2 and DNA mixture was added drop wise 
to the HBS.  The HBS, CaCl2, and DNA mixture was immediately added drop wise to 
approximately 60% confluent p100 plates containing Phoenix cells in 15% FBS/DMEM.  This 
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process was repeated for three plasmids: a control pOZFHN vector containing no construct, the 
pOZFHN vector containing the wild-type E2F8 sequence, and the pOZFHN vector containing a 
point mutation in the first DNA binding domain.  All transfected plates were incubated at 37ºC 
incubator for approximately 20 hours, at which point the media was removed and the cells were 
washed twice with PBS.  6 ml of media was placed on the cells and they continued to grow in the 
incubator.   
 
HeLa Cell Transduction: 
HeLa cells were thawed and split according to standard tissue culture protocol.  Virus was 
harvested from the transfected Phoenix cells by placing the virus containing media in 15 ml 
conicals with 3 ml of polybrene per p100.  The conicals were spun at 3800 rpm for 10 minutes.  
Meanwhile, media was added back to the Phoenix cell plates and these were placed back in the 
incubator.  HeLa plates with ~60% confluence were taken out of the incubator and the media was 
removed.  The supernatant was removed from the conicals without disturbing the virus pellet.  10 
ml of media was added to each tube and the pellets were re-suspended.  The contents from each 
conical were added to a plate containing HeLa cells.  The HeLa cells were incubated for 5 hours 
and then the virus was removed and the media was replaced.  Infections were repeated every 12 
hours for a total of three infections.  Cells were harvested for immunoblot analysis and E2F8 
expression verification. 
 
Magnetic Affinity Enrichment: 
Bead suspension was prepared by adding 5 ul per sample of anti-IL2Ralpha antibody-conjugated 
magnetic beads to 5% FBS/DMEM and vortexed. Infected HeLa cells were split to T175 flasks 
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and 1 ml of bead suspension was added to each.  The flasks were incubated at 37ºC for 30 
minutes with occasional shaking.  Bead binding was observed with a microscope.  The 
suspension was transferred to a T25.  The remaining cells were transferred using a PBS wash 
followed by 2 ml trypsinization.  Trypsin exposure was minimalized to prevent degradation of 
the surface marker and DMEM was added quickly to neutralize the solution after the cells were 
detached.  This suspension was also added to the T25 flask.  This procedure was repeated for all 
samples.  The T25 flasks were attached with a rubber band to a magnetic plate and stood 
vertically.  The plates were rocked gently to bring the cells within magnetic range.  After 30 
minutes, unbound cells were aspirated from the flasks along with the media.  50 ml of DMEM 
was added to each T25 to wash the cells.  The wash was repeated twice more.  The flasks were 
removed from the magnetic plates and 5 ml of DMEM/15% FBS was added to each flask.  Bead 
bound cells were observed under the microscope.  The cells were allowed to grow at 37ºC and 
the sorting procedure was repeated again up to four times.  Enrichment of E2F8 expression was 
verified by immunoblot analysis.   
 
Large Batch Suspension Culture Maintenance: 
Sorted HeLa cells were grown in 5 p150s per sample, the cells were counted, spun down, and 
then transferred to 2 liter flasks.  Media was changed from 15% FBS in DMEM to 10% Bovine 
Calf Serum (BCS) in Joklik medium.  Cell density was adjusted to 2 x 10^5 cells/ml.  The flasks 
were placed in a 37ºC water bath over stir plates and magnetic stir bars rotated the media at 
approximately 60 rpm.  Cell density was monitored every 24 hours and adjusted back to 2 x 10^5 
cells/ml by adding Joklik media and BCS.  As the volume increased, the cells were transferred to 
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12 liter flasks where the procedure was continued until 8 liters of cells at a density of ~1x10^6 
cells/ml was ready to harvest. 
 
Large Batch Harvest and Nuclear Extraction: 
The cells were harvested by centrifugation at 1000 g (~3000 rpm) for 10 minutes and suspended 
in 5 volumes of cold PBS.  The cells were maintained at 0-4ºC throughout the harvest.  The cells 
were spun down again at 1000 g for 10 minutes and suspended in five volumes of Buffer A (10 
mM Hepes (pH 7.9), 1.5 mM MgCl2, 10 mM KCl, 0.5 mM DTT, 0.5 mM PMSF).  The cells 
were left on ice for 10 minutes and then collected again by centrifugation.  The cells were 
suspended in 2 volumes of Buffer A and then homogenized by 10 strokes with a glass Dounce 
Homogenizer (B pestle).  The cells were checked microscopically for cell membrane lysis.  The 
nuclear membrane was intact at this point.  The homogenate was then centrifuged for 10 minutes 
at 1000 g.  The supernatant was decanted and the nuclear pellet was centrifuged for 20 minutes at 
25000 g.  The supernatant was discarded and the nuclear pellet was re-suspended in 2.5 ml per 
10^9 cells of Buffer C (20 mM Hepes (pH 7.9), 25% glycerol, 0.42 M NaCl, 1.5 mM Mg Cl2, 
0.2 mM EDTA, 0.5 mM PMSF, 0.5 mM DTT and 0.1% Tween).  This equates to approximately 
20 ml for each 8 liter preparation.  The nuclear pellet was then homogenized by 20 strokes of a 
glass Dounce Homogenizer and lysis was verified microscopically.  The homogenates were then 
rocked for 30 minutes.  The samples were then centrifuged for 30 minutes at 25000 g, and the 
supernatants transferred to 15 ml conicals.  At this point samples were either snap frozen in dry 
ice and stored in -80ºC, or were immediately used for immunopurification.   
 
Immuno-affinity Purification: 
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Frozen samples were quickly thawed in a 37ºC water bath, but were placed in ice before they 
were completely thawed to prevent complex degradation (the samples were always kept at or 
below 4ºC).  The lysates were then spun down at 50,000 g for 30 minutes.  The supernatants 
were transferred to fresh tubes and the step was repeated.  While the extracts were spinning, M2 
anti-FLAG antibody-conjugated agarose beads were prepared.  400 ul of beads per 10 ml of 
sample was washed in BioRad Poly-Prep Columns with 10 volumes of 100 mM glycine-HCl (pH 
2.5) to remove uncrosslinked antibody.  The beads were then washed with 10 bead volumes of 
0.2 M Tris-HCl (pH 8).  Buffer C was then used to wash the beads again (10 bead volumes).  
Then the column tip was capped and 1 bead volume of Buffer C was added to re-suspend the 
beads to a 50% slurry.  The beads were then added to the supernatants and rotated overnight.  
Between 9 and 12 hours later, a column for each sample was setup over a 50 ml conical.  The 
samples were then added to their respective column.  The samples were allowed to drain by 
gravity flow.  The flow through was then quick frozen and saved in -80ºC.  The columns were 
then placed over glass flasks and the samples were washed by filling the columns to the top with 
Buffer C.  The washing step was repeated twice more.  The columns were then setup over a 15 
ml conical and spun at 1200 g for 1 minute to remove excess liquid.  The column tips were then 
capped and 400 ul of FLAG elution buffer (150 ug/ml of FLAG peptide in Buffer C) was added 
to each column.  The columns were left in 4ºC for 1 hour.  The columns were then placed over 
15 ml conicals and spun at 1200 g for 1 minute.  The samples were then transferred to 1.5 ml 
eppendorf tubes.  About 50 ul of packed anti-HA 12CA5 antibody-conjugated beads were 
prepared per sample.  The beads were washed in 1.5 eppendorfs with glycine-HCl (pH 2.5) 
followed by a wash with 200 mM Tris-HCl (pH 8.0).  The beads were then re-suspended in 
Buffer C to a 50% slurry.  The beads were added to the FLAG eluents and rotated for 30 minutes 
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in the cold room.  The samples were then spun down at 14,000 rpm for <1 minute and the 
supernatant was snap frozen and saved in -80ºC.  The beads were then washed three times with 
2x the packed bead volume (100 ul) of Buffer C.  The same volume (100 ul) of elution buffer 
(150ug/ml HA peptide in Buffer C) was added to the beads.  The samples were incubated at 
room temperate for 30 minutes.  The samples were then spun down and the supernatant was 
transferred to a fresh eppendorf and preserved with 5x loading dye.  The samples were then 
stored at -80ºC and thawed for Western Blot analysis and Silver Stain analysis as needed.   
 
Western Blot Analysis: 
The immunopurified samples were separated in SDS polyacrylamide gels and transferred to 
polyvinylidene fluoride membranes. The membranes were rocked in blocking buffer (10% skim 
milk in Tris-buffered saline-Tween) for one hour at room temperature. The primary antibody was 
then added to 1% skim milk in Tris-buffered saline-Tween at a concentration specific to the 
tendencies of the particular antibody and rocked at 4ºC overnight (specific antibody conditions 
will be made available upon request).  The primary antibody was then bound to horseradish-
peroxidase-conjugated secondary antibody at a 1:5000 dilution in 2% skim milk in Tris-buffered 
saline-Tween at room temperature for 90 minutes. The secondary antibody was then detected by 
ECL reagent as described by the manufacturer (Amersham). 
 
Silver Stain Analysis: 
The immunopurified samples were separated in SDS polyacrylamide gels and then the gels were 
fixed overnight in 50% methanol, 12% acetic acid and 0.05% formaldehyde.  They were then 
washed 3 times for 20 minutes each in 50% ethanol.  The gels were pretreated for ~45 seconds 
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with 0.02% sodium thiosulfate.  They were then washed 3 times for 30 seconds in 50% 
methanol.  Immediately, the gels were impregnated with 0.2% silver nitrate, 0.075% 
formaldehyde impregnating solution for 20 minutes.  After impregnation, the gels were rinsed 
with H2O twice for 20 seconds each.  They were then allowed to develop (6% sodium carbonate, 
0.0004% sodium thiosulfate, 0.05% formaldehyde) between 30 seconds and 3 minutes depending 
on how quickly the reaction took place.  As soon as the resolution was preferable, the reaction 
was neutralized with 50% methanol, 12% acetic acid (22). 
 
Results 
 In order to verify the success of the subcloning, four plasmids, including three constructs, 
were transiently transfected into HeLa cells (tranfection protocol is identical to that found in 
Methods).  The first plasmid was an empty pOZFHN control vector and of course there was no 
E2F8 expression.  The second, third, and fourth plasmids were the wild-type E2F8 construct, the 
DBD-1 mutant, and the DBD-1,2 mutant all ligated into their respective pOZFHN vectors; 
expression was detected for all three via immunoblot analysis probed with anti-FLAG.  These 
specific mutant constructs have been shown to be unable to bind DNA (19). 
 Once the functional expression of the constructs was confirmed, packaging of the vectors 
into Phoenix cells was carried out.  HeLa cell infections followed and once again, successful 
expression was verified by probing a Western with anti-flag antibody.    
 HeLa cell expression was detectable but not concentrated.  In order to enrich the cell 
cultures, high-expressing cells were selected for using anti-IL2Ralpha antibody-conjugated 
magnetic beads.  Physical binding of the magnetic beads to the HeLa cells expressing the 
receptor were verified via microscopy (Fig. 3). The selection process was repeated a total of four 
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times, as this proved to be a sufficient number for maximal enrichment.  Cells from each 
enrichment round were harvested for Western blots.  These Western blots verified marked 
improvement in expression levels for each construct (Fig. 4). 
 Once maximal enrichment was achieved, large scale suspension cultures were initiated using 
the high-expressing cultures.  At this point, a problem was encountered: the wild-type E2F8 
over-expressing cells, despite the enrichment process, lost expression during the large-scale 
growth period.  Cells over-expressing E2F8 are greatly inhibited in their ability to proliferate (18, 
19).  Given this fact, it seems as though the low-expressing cells outgrew the high-expressing 
cells over time, thus diluting E2F8 expression.  This reduction in the presence of E2F8 made the 
large preps from this construct ultimately useless, as a great deal of protein is needed for 
detection purposes.  As a consequence of this, an alternate course was sought.  Given that the 
mutant constructs maintain the ability to homodimerize (19), it was decided that the DBD-1 
mutant would be used.  An E2F8 protein with mutations in one or both of its DNA binding 
domains prevents its ability to successfully bind target promoters.  With this ability hindered, the 
mutant E2F8 cannot affect cellular division and thus cannot inhibit the growth of high-
expressing cells.  Therefore the DBD-1 mutant was able to be grown up in large, 8 liter 
suspension cultures in stead of the wild-type cell line. 
 Two 8 liter cultures were grown up in parallel: the DBD-1 mutant cell line and a cell line 
containing the empty vector control.  These cultures were harvested simultaneously.  The cells 
were lysed in such a way as to separate the cytoplasmic content from the nuclear content.  As 
evidenced by the presence of a nuclear localization signal, data from immunofluorescent staining 
(19), and given that E2F8 is a transcription factor, it is known that E2F8 resides in the nucleus. 
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This method of harvesting allowed for further concentration of the E2F8 level in the lysate (Fig. 
5).      
 Nuclear lysates from the DBD-1 mutant and control vector were snap-frozen and stored at -
80ºC.  These samples were quick thawed in 37ºC and bound to M2 anti-FLAG antibody-
conjugated agarose beads.  The columns were washed and the bound products were eluted.  
Samples from the flow through, wash, beads, and eluent were all saved for Western blot analysis 
(Fig. 6).  After several FLAG purification rounds, standard conditions were arrived at for 
optimized binding and elution.  Following the FLAG elution, the eluents were then to be bound 
to anti-HA 12CA5 antibody-conjugated beads.  Unfortunately, the HA purification step proved 
much more fickle, which made the standardization difficult.  The challenges were to ensure that 
E2F8 bound efficiently to the antibody, as the majority of E2F8 tended to remain in solution and 
consequently was extracted with the flow through, and to ensure that the complexes remained 
intact throughout the HA purification.  Several methods remedied this: an increase in the number 
of HA beads, an increase in binding time, and a decrease in salt concentration from 420 mM to 
150 mM (Fig. 8).  The lower salt stringency likely allowed for more binding partners to remain 
during the washes.  Other final changes that were made to the initial protocol include an increase 
in protease inhibitors to prevent complex degradation and HA column elution using Glycine pH 
2.5 instead of HA peptide competition.  These changes allowed for a clean and robust E2F8 
sequential purification protocol as evident by silver stain analysis (Fig. 8).   
 Despite the setbacks, two E2F8 binding partners were identified, and these were used to 
verify successful complex purification via immunoblot analysis.  The first identified binding 
partner and most likely candidate was histone deacetylase-1 (HDAC-1).  HDACs are chromatin 
modifiers and consequent transcriptional regulators.  They repress gene expression by 
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deacetylating the beta-amino acids of lysine located near the amino termini of core histone 
proteins.  As HDAC proteins are known to aid repressive complexes, it was a likely candidate for 
E2F8 binding.  In order to discover E2F8/HDAC binding, anti-HDAC-1 antibody was used to 
probe Western blots containing FLAG immunopurified samples (Fig. 7).   SIN3A was detected 
the way HDAC-1 was, by using an anti-SIN3A antibody to probe a Western containing the 
immunopurified lysates.  SIN3A is thought to be a scaffolding protein in repressive complexes.  
HDAC is known to directly bind to SIN3A (10), which suggests that E2F8 binds to SIN3A and 
SIN3A binds to HDAC.  Although HDAC-1 was purified by using E2F8, it is likely that it does 
not directly interact with E2F8 but is actually held in the complex by SIN3A.   
 
Discussion 
Since the HA purification step had proven so difficult to replicate, mass-spectrometric 
analysis has not yet been pursued.  However, there are now ample reserves of purified E2F8 
complexes prepared for mass-spectrometric analysis.  It is now simply a matter of identifying 
novel proteins linked specifically to E2F8.  The newly identified binding partners will be verified 
via immunopurification and western blot analysis.  Once the identities are confirmed, new paths 
and directions will be taken to elucidate the function of E2F8. 
 It is difficult to predict what E2F8 binding proteins will be identified in the near future.  
Likely candidates are proteins typically found in repressive complexes, such as chromatin 
modifiers like HDAC, other proteins contained in the SIN3 complex (SIN3B), and methyl 
transferases.  Perhaps E2F8 interacts with polycomb group proteins like E2F6 does.  It is known 
that E2F8 can dimerize with E2F7, and that E2F7 binds with CTBP (Li, Gordon, Leone, 
unpublished data).  The mass-spectrometry results should prove very interesting. 
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 Once results are available from mass-spectrometric analysis and novel binding partners are 
identified, it may be worthwhile to repeat the experiment again, only this time with a retroviral 
vector containing the wild-type E2F8 sequence expressed under a tetracycline-regulatable 
promoter.  This system would allow for high E2F8 expressing cells to be selected for, enriched, 
and then collectively silenced in respect to E2F8 expression.  The ability to turn off E2F8 
production would allow for large-scale liquid culture preparation without losing concentrated 
expression.  Before the large batch is harvested, the repression system would be removed and 
E2F8 expression would be activated.  The benefit to this system is obvious: wild-type E2F8 
could be used instead of the mutant construct.  The reason this would be preferable is because 
some repressive complexes do not exist without an initial interaction.  It is possible that the 
initial interaction for E2F8 is DNA binding; this DNA binding event may cause a tertiary 
rearrangement in the protein, thus opening binding pockets for other proteins to be recruited.  
This idea is pure speculation and is simply a suggestion for further experimental pursuit; it ought 
to be a consideration pending the mass-spectrometric results of this experiment.   
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Figure 1.  An illustration of an example of a protein complex recruited to a target promoter by 
the transcription factor E2F8.  The complex forms to prevent expression of the downstream gene.  
Some or all of the proteins are needed to accomplish affective repression.  If any of the co-
factors are unable to bind, uncontrolled expression may occur, and in the case of E2F pathways, 
a tumor may eventually form. 
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Figure 2. An illustration of the sequential immunopurification scheme.  The FLAG epitope is 
able to bind in the first purification round (top), and consequently the E2F8 complex is also 
bound.  All unbound material is washed away and discarded.  Following elution, the sample is 
bound to HA beads (bottom) using the HA antigen.  Once again, the complex is held in place 
while all unbound material is washed away.  Any background material accumulated during the 
FLAG purification should be washed away during the HA purification. 
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E2F8 DBD-1 E2F8 WT Control 
 
Figure 3. The upper left picture shows HeLa cells over-expressing E2F8 DBD-1 mutant protein. 
Consequently they are also expressing the IL2Ralpha receptor.  The receptor is recognized by the 
anti-IL2Ralpha antibody-conjugated magnetic beads, which are bound to the surface of the cells 
displaying the protein.  The orange circles are the beads.  The center two pictures are also 
displaying the magnetic beads bound to HeLa cells, although these cells are over-expressing 
wild-type E2F8 instead of the DBD-1 mutant.  The right most picture is the empty vector 
control; because the cells are not expressing a construct, the receptor protein is not expressed and 
no beads are bound. 
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Figure 4. Western results for two gels containing samples saved from the magnetic bead sorting 
round.  Both membranes were probed with anti-FLAG antibody.  The top gel shows the 
progressive increase in E2F8 concentration for the wild-type cell line as compared to the empty 
vector control, where no change was seen.  Untransfected HeLa cell lysate was also run as 
another control.  The bottom gel shows the same enrichment process for the DBD-1 mutant cell 
line. HeLa lysate was run as a control. 
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Figure 5. A Western blot showing the sub-cellular localization of E2F8 and the successful 
nuclear harvest of HeLa cells over-expressing the construct.  Untransfected HeLa cell lysate was 
run as a negative control.  Sorted HeLa cells over-expressing E2F8 were harvested in a typical 
manner and run as a positive control. The nuclear extract contained E2F8 (~110 Kb) while E2F8 
was undetectable in the cytoplasmic extract. 
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Figure 6. A Western blot showing the results of a FLAG purification.  The left most lane is the 
flow through (unbound protein).  To the right of that is the bound portion of protein at that point 
of the purification.  To the right of that is what flowed through with the first wash.  Next to that 
lane is the first eluent.  To the right of the first eluent is the protein remaining bound after the 
first elution, which was eluted the second time.  To the right of that are the proteins that did not 
elute but remained bound to the beads.  After the ladder is the nuclear lysate (before IP) control 
lane, then the total cell lysate positive control, and finally, the total cell lysate negative control.  
Not all of the E2F8 protein eluted efficiently.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 25
 
 
 
250 KD
150 KD
100 KD
75 KD
50 KD
co
nt
ro
l
Fl
ag
-H
A
-E
2F
8
IB: α-Flag
250 KD
150 KD
100 KD
75 KD
co
nt
ro
l
Fl
ag
-H
A
-E
2F
8
co
nt
ro
l
Fl
ag
-H
A
-E
2F
8
IB: α-HDAC1
Fl
ag
-H
A
-E
2F
8
250 KD
150 KD
100 KD
75 KD
50 KD
37 KD
co
nt
ro
l
IB: α-Sin3A  
 
Figure 7.  Three separate Western blots probed with three different antibodies.  Each immunoblot 
contains FLAG immunopurified samples.  The left picture shows E2F8 after FLAG 
immunopurification as compared to the empty vector control.  The center picture shows the same 
samples probed with anti-HDAC-1 antibody.  The right picture shows the same two samples as 
the other blots probed with anti-SIN3A antibody.  This data confirms that the complexes were in 
fact intact and purified along with E2F8 through the FLAG purification. 
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Figure 8.  Two silver stained polyacrylamide denaturing gels, the left most is a 5%-20% gradient 
gel; the right is a standard 8% gel.  Both gels contain the same samples.  The left lane in each gel 
is FLAG and HA purified HeLa cell nuclear extract.  The center lanes contains FLAG and HA 
purified nuclear lysate from HeLa cells over-expressing E2F8 DBD-1 mutant.  The right most 
lanes contain FLAG and HA purified nuclear lysate from HeLa cells over-expressing E2F7 
DBD-1 mutant.    
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